Alpha thalassemia
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Alpha-thalassemia is a group of diseases that are common in Southeast Asia, China, Africa, and the Mediterranean. Two almost identical copies of the alpha globin gene are located on chromosome 16. In 80–85% of cases of alpha thalassemia, one or more of these four genes are lost. The rest of the patients, these genes are preserved, but not functioning.
The clinical manifestations of alpha-thalassemia correlate with the degree of impaired synthesis of the alpha-globin chain, but they are usually less pronounced than with β-thalassemia. This is due, firstly, to the fact that the presence of four alpha-globin genes contributes to the formation of an adequate number of alpha chains until three or four genes are lost. A significant imbalance of hemoglobin chains occurs only if three of the four genes are affected. Secondly, β-chain aggregates (β1 tetramers are formed when alpha chains are deficient) are more soluble than alpha 4 tetramers, and therefore even in patients with significantly impaired alpha globin synthesis with alpha thalassemia hemolysis is much weaker, and erythropoiesis more effective than β-thalassemia.
Alpha-Thalassemia (alpha-tal) is a hemolytic anemia caused by a deficiency in the synthesis of a-globin as a result of the loss or damage of one or more alpha-globin genes. The decrease in alpha-chain synthesis leads to the accumulation of free γ- and β-chains and the formation of tetramers-γ 4 (Hb Bart's) and unstable β 4 (Hb H) from them, followed by acceleration of erythrocyte destruction. Possessing a very high affinity for oxygen, these tetramers cannot perform the function of oxygen transfer. Thus, the clinical picture of severe alpha-tal is characterized by a combination of hypochromic anemia, hemolysis, and defective oxygen transport due to varying amounts of physiologically ineffective hemoglobin in erythrocytes. As a result, the degree of tissue hypoxia is much higher than expected with an appropriate degree of anemia.
There are 4 groups of clinical syndromes alpha-tal:
- silent carriage;
- alpha thalassemia with minimal changes;
- hemoglobinopathy H;
- alpha-thalassemic fetal dropsy.
The severity of the phenotypic manifestation of alpha-tal is directly proportional to the decrease in alpha-globin synthesis.
Silent carrier state (alpha-tal-2 heterozygotes)
Phenotypically dumb alpha-tal carriers differ little from healthy children. MCV is usually in the range of 78-80 fl, while the MCH can correspond to the lower limit of the norm. All other hematologic parameters are normal. Some dumb carriers may even have normal MCV values in the 80-85 fl range. In the blood of some of them, in the neonatal period, small amounts of Hb Bart's (<2%) disappear during the first months of life.
Small alpha-thalassemia-2 (asymptomatic carriage) - due to the loss of two alpha-globin genes on different chromosomes (trans-form). It is found in the inhabitants of Asia, Africa, and the Mediterranean. Hematological parameters do not differ from the norm; no clinical manifestations. In the neonatal period, an increased amount of Bart Hb is determined - 0.8-5%. In adults with a-thalassemia-2, the pathological HbH fractions of hemoglobin H Bart are not detected, the HbA 2 and HbF levels are normal.
[